VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q58467781 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241121000200.0
008 241121nneanz||abbn n and d
035 ‎‡a (WKP)Q58467781‏
024 ‎‡a 0000-0002-2600-0485‏ ‎‡2 orcid‏
035 ‎‡a (OCoLC)Q58467781‏
100 0 ‎‡a Francisco J. García-Hernandez‏ ‎‡c researcher ORCID ID = 0000-0002-2600-0485‏ ‎‡9 en‏
375 ‎‡a 1‏ ‎‡2 iso5218‏
400 0 ‎‡a Francisco J. García-Hernandez‏ ‎‡c wetenschapper‏ ‎‡9 nl‏
670 ‎‡a Author's A combined large-scale meta-analysis identifies COG6 as a novel shared risk locus for rheumatoid arthritis and systemic lupus erythematosus‏
670 ‎‡a Author's A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations‏
670 ‎‡a Author's A replication study confirms the association of TNFSF4‏
670 ‎‡a Author's A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with Systemic Sclerosis in a large European cohort.‏
670 ‎‡a Author's [Alfa-2b interferon-induced systemic lupus erythematosus in a patient with hepatitis C virus chronic infection]‏
670 ‎‡a Author's An MIF Promoter Polymorphism Is Associated with Susceptibility to Pulmonary Arterial Hypertension in Diffuse Cutaneous Systemic Sclerosis.‏
670 ‎‡a Author's Analysis of ancestral and functionally relevant CD5 variants in systemic lupus erythematosus patients‏
670 ‎‡a Author's Anti-centromere antibodies in patients with systemic lupus erythematosus.‏
670 ‎‡a Author's [Antiprothrombin antibodies in a patient with secondary antiphospholipid syndrome and bleeding]‏
670 ‎‡a Author's Association Between −174 Interleukin-6 Gene Polymorphism and Biological Response to Rituximab in Several Systemic Autoimmune Diseases‏
670 ‎‡a Author's Association of a non-synonymous functional variant of the ITGAM gene with systemic sclerosis‏
670 ‎‡a Author's Association of haplotypes of the TLR8 locus with susceptibility to Crohn's and Behçet's diseases‏
670 ‎‡a Author's Association of the FCGR3A-158F/V Gene Polymorphism with the Response to Rituximab Treatment in Spanish Systemic Autoimmune Disease Patients‏
670 ‎‡a Author's Association study of genetic variants of pro-inflammatory chemokine and cytokine genes in systemic lupus erythematosus‏
670 ‎‡a Author's Autoimmune polyglandular syndrome and pulmonary arterial hypertension‏
670 ‎‡a Author's [Biological markers. Utility in the management of patients with pulmonary hypertension].‏
670 ‎‡a Author's Bone mass and vitamin D in patients with systemic sclerosis from two Spanish regions‏
670 ‎‡a Author's Clinical and epidemiological differences between men and women with systemic sclerosis: a study in a Spanish systemic sclerosis cohort and literature review‏
670 ‎‡a Author's [Clinical and epidemiological features and HLA association in patients with pars planitis]‏
670 ‎‡a Author's Clinical manifestations and long-term outcome of anti-Jo1 antisynthetase patients in a large cohort of Spanish patients from the GEAS-IIM group.‏
670 ‎‡a Author's [Coexistence of antitopoisomerase I and anticentromere antibodies in systemic sclerosis]‏
670 ‎‡a Author's Combined treatment with intravenous prostacyclin and sildenafil in patients with pulmonary hypertension: report of 4 cases‏
670 ‎‡a Author's [Complete auriculoventricular blockage in adult patients with systemic lupus erythematosus. Case series and a review of the literature]‏
670 ‎‡a Author's Confirmation of association of the macrophage migration inhibitory factor gene with systemic sclerosis in a large European population‏
670 ‎‡a Author's Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis.‏
670 ‎‡a Author's Correction: Identification of Novel Genetic Markers Associated with Clinical Phenotypes of Systemic Sclerosis through a Genome-Wide Association Strategy.‏
670 ‎‡a Author's Differential expression pattern of microRNAs in CD4+ and CD19+ cells from asymptomatic patients with systemic lupus erythematosus‏
670 ‎‡a Author's Effects of rituximab in connective tissue disorders related interstitial lung disease‏
670 ‎‡a Author's [Efficacy of rituximab combined with cyclophosphamide in a patient with systemic lupus erythematosus and peritoneal vasculitis refractory to conventional inmunosupressive therapy]‏
670 ‎‡a Author's [Encephalitis due to Epstein-Barr virus in an adult]‏
670 ‎‡a Author's [Evaluation of the effectiveness of treatment with rituximab associated to cyclophosphamide in patients with resistant idiopathic inflammatory myopathy]‏
670 ‎‡a Author's Evidence of new risk genetic factor to systemic lupus erythematosus: the UBASH3A gene.‏
670 ‎‡a Author's Experience with imatinib to treat pulmonary arterial hypertension‏
670 ‎‡a Author's Experience with rituximab in the treatment of systemic erythematosus lupus‏
670 ‎‡a Author's First clinical symptom as a prognostic factor in systemic sclerosis: results of a retrospective nationwide cohort study.‏
670 ‎‡a Author's Health-related internet use by lupus patients in southern Spain‏
670 ‎‡a Author's [Hypersensitivity response to cyclophosphamide in a patient with systemic lupus erythematous]‏
670 ‎‡a Author's Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association Study follow-up‏
670 ‎‡a Author's Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy‏
670 ‎‡a Author's IL2/IL21 region polymorphism influences response to rituximab in systemic lupus erythematosus patients.‏
670 ‎‡a Author's Iliopsoas abscess and systemic lupus erythematosus‏
670 ‎‡a Author's Iloprost for severe Raynaud's phenomenon and ischaemic ulcers related with systemic diseases‏
670 ‎‡a Author's Influence of antibody profile in clinical features and prognosis in a cohort of Spanish patients with systemic sclerosis‏
670 ‎‡a Author's Influence of the IL6 gene in susceptibility to systemic sclerosis‏
670 ‎‡a Author's Influence of the STAT3 genetic variants in the susceptibility to psoriatic arthritis and Behcet’s disease‏
670 ‎‡a Author's [Intestinal vasculitis and dermatomyositis in the adult]‏
670 ‎‡a Author's [Isotopic ventriculography in patient with severe pulmonary hypertension]‏
670 ‎‡a Author's Lack of association of TNFAIP3 and JAK1 with Behçet's disease in the European population.‏
670 ‎‡a Author's Mutational profile of rare variants in inflammasome-related genes in Behçet disease: A Next Generation Sequencing approach‏
670 ‎‡a Author's No evidence for association between the CCR5/Delta32CCR5 polymorphism and systemic sclerosis‏
670 ‎‡a Author's No evidence of association between functional polymorphisms located within IL6R and IL6ST genes and systemic sclerosis.‏
670 ‎‡a Author's Novel identification of the IRF7 region as an anticentromere autoantibody propensity locus in systemic sclerosis‏
670 ‎‡a Author's Polymorphisms of the FCRL3 gene in a Spanish population of systemic lupus erythematosus patients‏
670 ‎‡a Author's [Prinzmetals angina pectoris: an unusual clinical manifestation of Churg-Strauss syndrome]‏
670 ‎‡a Author's [Pulmonary arterial hypertension]‏
670 ‎‡a Author's [Pulmonary hypertension in a patient with neurofibromatosis]‏
670 ‎‡a Author's Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status.‏
670 ‎‡a Author's Rituximab for treatment of patients with systemic autoimmune diseases‏
670 ‎‡a Author's Rituximab is effective in the treatment of patients with idiopathic inflammatory myopathy‏
670 ‎‡a Author's Screening of pulmonary hypertension in a Spanish cohort of patients with systemic sclerosis‏
670 ‎‡a Author's [Severe imatinib-induced hepatotoxicity]‏
670 ‎‡a Author's [Severe infections in a cohort of patients with systemic lupus erythematosus]‏
670 ‎‡a Author's [Soft tissue visualization with 99m Tc-HDP in a case of dermatomyositis]‏
670 ‎‡a Author's The autoimmune disease-associated IL2RA locus is involved in the clinical manifestations of systemic sclerosis‏
670 ‎‡a Author's Tocilizumab for treating refractory haemolytic anaemia in a patient with systemic lupus erythematosus‏
670 ‎‡a Author's Transverse myelitis in systemic lupus erythematosus‏
670 ‎‡a Author's [Treatment with rituximab of autoimmune disease: results from AADEA's registry]‏
670 ‎‡a Author's [Tuberculosis in a cohort of patients with systemic lupus erythematosus].‏
670 ‎‡a Author's Usefulness of brain SPECT with HMPAO-99mTc and psychological tests for diagnosis of neurological involvement in Behçet's disease‏
670 ‎‡a Author's Variants of the IFI16 gene affecting the levels of expression of mRNA are associated with susceptibility to Behçet disease.‏
670 ‎‡a Author's Vasculitis del sistema nervioso central de presentación seudotumoral en la artritis reumatoide‏
670 ‎‡a Author's Venous thrombosis and relapses in patients with Behçet's disease. Descriptive analysis from Spanish network of Behçet's disease (REGEB cohort)‏
670 ‎‡a Author's [Vogt-Koyanagi-Harada disease. Characteristics of a series of Andalusian patients]‏
909 ‎‡a (orcid) 0000000226000485‏ ‎‡9 1‏
912 ‎‡a replicationstudyconfirmstheassociationoftnfsf4ox40lpolymorphismswithsystemicsclerosisinalargeeuropeancohort‏ ‎‡A A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with Systemic Sclerosis in a large European cohort.‏ ‎‡9 1‏
912 ‎‡a correctionidentificationofnovelgeneticmarkersassociatedwithclinicalphenotypesofsystemicsclerosisthroughagenomewideassociationstrategy‏ ‎‡A Correction: Identification of Novel Genetic Markers Associated with Clinical Phenotypes of Systemic Sclerosis through a Genome-Wide Association Strategy.‏ ‎‡9 1‏
912 ‎‡a identificationofnovelgeneticmarkersassociatedwithclinicalphenotypesofsystemicsclerosisthroughagenomewideassociationstrategy‏ ‎‡A Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy‏ ‎‡9 1‏
919 ‎‡a gwasfollowupstudyrevealstheassociationoftheil12rb2genewithsystemicsclerosisincaucasianpopulations‏ ‎‡A A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations‏ ‎‡9 1‏
919 ‎‡a alfa2binterferoninducedsystemiclupuserythematosusinapatientwithhepatitis100viruschronicinfection‏ ‎‡A [Alfa-2b interferon-induced systemic lupus erythematosus in a patient with hepatitis C virus chronic infection]‏ ‎‡9 1‏
919 ‎‡a mifpromoterpolymorphismisassociatedwithsusceptibilitytopulmonaryarterialhypertensionindiffusecutaneoussystemicsclerosis‏ ‎‡A An MIF Promoter Polymorphism Is Associated with Susceptibility to Pulmonary Arterial Hypertension in Diffuse Cutaneous Systemic Sclerosis.‏ ‎‡9 1‏
919 ‎‡a analysisofancestralandfunctionallyrelevantcd5variantsinsystemiclupuserythematosuspatients‏ ‎‡A Analysis of ancestral and functionally relevant CD5 variants in systemic lupus erythematosus patients‏ ‎‡9 1‏
919 ‎‡a anticentromereantibodiesinpatientswithsystemiclupuserythematosus‏ ‎‡A Anti-centromere antibodies in patients with systemic lupus erythematosus.‏ ‎‡9 1‏
919 ‎‡a antiprothrombinantibodiesinapatientwithsecondaryantiphospholipidsyndromeandbleeding‏ ‎‡A [Antiprothrombin antibodies in a patient with secondary antiphospholipid syndrome and bleeding]‏ ‎‡9 1‏
919 ‎‡a associationbetween174interleukin6genepolymorphismandbiologicalresponsetorituximabinseveralsystemicautoimmunediseases‏ ‎‡A Association Between −174 Interleukin-6 Gene Polymorphism and Biological Response to Rituximab in Several Systemic Autoimmune Diseases‏ ‎‡9 1‏
919 ‎‡a associationofanonsynonymousfunctionalvariantoftheitgamgenewithsystemicsclerosis‏ ‎‡A Association of a non-synonymous functional variant of the ITGAM gene with systemic sclerosis‏ ‎‡9 1‏
919 ‎‡a associationofhaplotypesofthetlr8locuswithsusceptibilitytocrohnsandbehcetsdiseases‏ ‎‡A Association of haplotypes of the TLR8 locus with susceptibility to Crohn's and Behçet's diseases‏ ‎‡9 1‏
919 ‎‡a associationofthefcgr3a158f5genepolymorphismwiththeresponsetorituximabtreatmentinspanishsystemicautoimmunediseasepatients‏ ‎‡A Association of the FCGR3A-158F/V Gene Polymorphism with the Response to Rituximab Treatment in Spanish Systemic Autoimmune Disease Patients‏ ‎‡9 1‏
919 ‎‡a associationstudyofgeneticvariantsofproinflammatorychemokineandcytokinegenesinsystemiclupuserythematosus‏ ‎‡A Association study of genetic variants of pro-inflammatory chemokine and cytokine genes in systemic lupus erythematosus‏ ‎‡9 1‏
919 ‎‡a autoimmunepolyglandularsyndromeandpulmonaryarterialhypertension‏ ‎‡A Autoimmune polyglandular syndrome and pulmonary arterial hypertension‏ ‎‡9 1‏
919 ‎‡a biologicalmarkersutilityinthemanagementofpatientswithpulmonaryhypertension‏ ‎‡A [Biological markers. Utility in the management of patients with pulmonary hypertension].‏ ‎‡9 1‏
919 ‎‡a bonemassandvitamin500inpatientswithsystemicsclerosisfrom2spanishregions‏ ‎‡A Bone mass and vitamin D in patients with systemic sclerosis from two Spanish regions‏ ‎‡9 1‏
919 ‎‡a clinicalandepidemiologicaldifferencesbetweenmenandwomenwithsystemicsclerosisastudyinaspanishsystemicsclerosiscohortandliteraturereview‏ ‎‡A Clinical and epidemiological differences between men and women with systemic sclerosis: a study in a Spanish systemic sclerosis cohort and literature review‏ ‎‡9 1‏
919 ‎‡a clinicalandepidemiologicalfeaturesandhlaassociationinpatientswithparsplanitis‏ ‎‡A [Clinical and epidemiological features and HLA association in patients with pars planitis]‏ ‎‡9 1‏
919 ‎‡a clinicalmanifestationsandlongtermoutcomeofantijo1antisynthetasepatientsinalargecohortofspanishpatientsfromthegeasiimgroup‏ ‎‡A Clinical manifestations and long-term outcome of anti-Jo1 antisynthetase patients in a large cohort of Spanish patients from the GEAS-IIM group.‏ ‎‡9 1‏
919 ‎‡a coexistenceofantitopoisomerase1andanticentromereantibodiesinsystemicsclerosis‏ ‎‡A [Coexistence of antitopoisomerase I and anticentromere antibodies in systemic sclerosis]‏ ‎‡9 1‏
919 ‎‡a combinedtreatmentwithintravenousprostacyclinandsildenafilinpatientswithpulmonaryhypertensionreportof4cases‏ ‎‡A Combined treatment with intravenous prostacyclin and sildenafil in patients with pulmonary hypertension: report of 4 cases‏ ‎‡9 1‏
919 ‎‡a completeauriculoventricularblockageinadultpatientswithsystemiclupuserythematosuscaseseriesandareviewoftheliterature‏ ‎‡A [Complete auriculoventricular blockage in adult patients with systemic lupus erythematosus. Case series and a review of the literature]‏ ‎‡9 1‏
919 ‎‡a confirmationofassociationofthemacrophagemigrationinhibitoryfactorgenewithsystemicsclerosisinalargeeuropeanpopulation‏ ‎‡A Confirmation of association of the macrophage migration inhibitory factor gene with systemic sclerosis in a large European population‏ ‎‡9 1‏
919 ‎‡a confirmationofccr6asariskfactorforantitopoisomerase1antibodiesinsystemicsclerosis‏ ‎‡A Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis.‏ ‎‡9 1‏
919 ‎‡a differentialexpressionpatternofmicrornasincd4+andcd19+cellsfromasymptomaticpatientswithsystemiclupuserythematosus‏ ‎‡A Differential expression pattern of microRNAs in CD4+ and CD19+ cells from asymptomatic patients with systemic lupus erythematosus‏ ‎‡9 1‏
919 ‎‡a effectsofrituximabinconnectivetissuedisordersrelatedinterstitiallungdisease‏ ‎‡A Effects of rituximab in connective tissue disorders related interstitial lung disease‏ ‎‡9 1‏
919 ‎‡a efficacyofrituximabcombinedwithcyclophosphamideinapatientwithsystemiclupuserythematosusandperitonealvasculitisrefractorytoconventionalinmunosupressivetherapy‏ ‎‡A [Efficacy of rituximab combined with cyclophosphamide in a patient with systemic lupus erythematosus and peritoneal vasculitis refractory to conventional inmunosupressive therapy]‏ ‎‡9 1‏
919 ‎‡a encephalitisduetoepsteinbarrvirusinanadult‏ ‎‡A [Encephalitis due to Epstein-Barr virus in an adult]‏ ‎‡9 1‏
919 ‎‡a evaluationoftheeffectivenessoftreatmentwithrituximabassociatedtocyclophosphamideinpatientswithresistantidiopathicinflammatorymyopathy‏ ‎‡A [Evaluation of the effectiveness of treatment with rituximab associated to cyclophosphamide in patients with resistant idiopathic inflammatory myopathy]‏ ‎‡9 1‏
919 ‎‡a evidenceofnewriskgeneticfactortosystemiclupuserythematosustheubash3agene‏ ‎‡A Evidence of new risk genetic factor to systemic lupus erythematosus: the UBASH3A gene.‏ ‎‡9 1‏
919 ‎‡a experiencewithimatinibtotreatpulmonaryarterialhypertension‏ ‎‡A Experience with imatinib to treat pulmonary arterial hypertension‏ ‎‡9 1‏
919 ‎‡a experiencewithrituximabinthetreatmentofsystemicerythematosuslupus‏ ‎‡A Experience with rituximab in the treatment of systemic erythematosus lupus‏ ‎‡9 1‏
919 ‎‡a 1clinicalsymptomasaprognosticfactorinsystemicsclerosisresultsofaretrospectivenationwidecohortstudy‏ ‎‡A First clinical symptom as a prognostic factor in systemic sclerosis: results of a retrospective nationwide cohort study.‏ ‎‡9 1‏
919 ‎‡a healthrelatedinternetusebylupuspatientsinsouthernspain‏ ‎‡A Health-related internet use by lupus patients in southern Spain‏ ‎‡9 1‏
919 ‎‡a hypersensitivityresponsetocyclophosphamideinapatientwithsystemiclupuserythematous‏ ‎‡A [Hypersensitivity response to cyclophosphamide in a patient with systemic lupus erythematous]‏ ‎‡9 1‏
919 ‎‡a identificationofcskasasystemicsclerosisgeneticriskfactorthroughgenomewideassociationstudyfollowup‏ ‎‡A Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association Study follow-up‏ ‎‡9 1‏
919 ‎‡a il2il21regionpolymorphisminfluencesresponsetorituximabinsystemiclupuserythematosuspatients‏ ‎‡A IL2/IL21 region polymorphism influences response to rituximab in systemic lupus erythematosus patients.‏ ‎‡9 1‏
919 ‎‡a iliopsoasabscessandsystemiclupuserythematosus‏ ‎‡A Iliopsoas abscess and systemic lupus erythematosus‏ ‎‡9 1‏
919 ‎‡a iloprostforsevereraynaudsphenomenonandischaemiculcersrelatedwithsystemicdiseases‏ ‎‡A Iloprost for severe Raynaud's phenomenon and ischaemic ulcers related with systemic diseases‏ ‎‡9 1‏
919 ‎‡a influenceofantibodyprofileinclinicalfeaturesandprognosisinacohortofspanishpatientswithsystemicsclerosis‏ ‎‡A Influence of antibody profile in clinical features and prognosis in a cohort of Spanish patients with systemic sclerosis‏ ‎‡9 1‏
919 ‎‡a influenceoftheil6geneinsusceptibilitytosystemicsclerosis‏ ‎‡A Influence of the IL6 gene in susceptibility to systemic sclerosis‏ ‎‡9 1‏
919 ‎‡a influenceofthestat3geneticvariantsinthesusceptibilitytopsoriaticarthritisandbehcetsdisease‏ ‎‡A Influence of the STAT3 genetic variants in the susceptibility to psoriatic arthritis and Behcet’s disease‏ ‎‡9 1‏
919 ‎‡a intestinalvasculitisanddermatomyositisintheadult‏ ‎‡A [Intestinal vasculitis and dermatomyositis in the adult]‏ ‎‡9 1‏
919 ‎‡a isotopicventriculographyinpatientwithseverepulmonaryhypertension‏ ‎‡A [Isotopic ventriculography in patient with severe pulmonary hypertension]‏ ‎‡9 1‏
919 ‎‡a lackofassociationoftnfaip3andjak1withbehcetsdiseaseintheeuropeanpopulation‏ ‎‡A Lack of association of TNFAIP3 and JAK1 with Behçet's disease in the European population.‏ ‎‡9 1‏
919 ‎‡a mutationalprofileofrarevariantsininflammasomerelatedgenesinbehcetdiseaseanextgenerationsequencingapproach‏ ‎‡A Mutational profile of rare variants in inflammasome-related genes in Behçet disease: A Next Generation Sequencing approach‏ ‎‡9 1‏
919 ‎‡a noevidenceforassociationbetweentheccr5delta32ccr5polymorphismandsystemicsclerosis‏ ‎‡A No evidence for association between the CCR5/Delta32CCR5 polymorphism and systemic sclerosis‏ ‎‡9 1‏
919 ‎‡a noevidenceofassociationbetweenfunctionalpolymorphismslocatedwithinil6randil6stgenesandsystemicsclerosis‏ ‎‡A No evidence of association between functional polymorphisms located within IL6R and IL6ST genes and systemic sclerosis.‏ ‎‡9 1‏
919 ‎‡a novelidentificationoftheirf7regionasananticentromereautoantibodypropensitylocusinsystemicsclerosis‏ ‎‡A Novel identification of the IRF7 region as an anticentromere autoantibody propensity locus in systemic sclerosis‏ ‎‡9 1‏
919 ‎‡a polymorphismsofthefcrl3geneinaspanishpopulationofsystemiclupuserythematosuspatients‏ ‎‡A Polymorphisms of the FCRL3 gene in a Spanish population of systemic lupus erythematosus patients‏ ‎‡9 1‏
919 ‎‡a prinzmetalsanginapectorisanunusualclinicalmanifestationofchurgstrausssyndrome‏ ‎‡A [Prinzmetals angina pectoris: an unusual clinical manifestation of Churg-Strauss syndrome]‏ ‎‡9 1‏
919 ‎‡a pulmonaryarterialhypertension‏ ‎‡A [Pulmonary arterial hypertension]‏ ‎‡9 1‏
919 ‎‡a pulmonaryhypertensioninapatientwithneurofibromatosis‏ ‎‡A [Pulmonary hypertension in a patient with neurofibromatosis]‏ ‎‡9 1‏
919 ‎‡a registryofthespanishnetworkforsystemicsclerosisclinicalpatternaccordingtocutaneoussubsetsandimmunologicalstatus‏ ‎‡A Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status.‏ ‎‡9 1‏
919 ‎‡a rituximabfortreatmentofpatientswithsystemicautoimmunediseases‏ ‎‡A Rituximab for treatment of patients with systemic autoimmune diseases‏ ‎‡9 1‏
919 ‎‡a rituximabiseffectiveinthetreatmentofpatientswithidiopathicinflammatorymyopathy‏ ‎‡A Rituximab is effective in the treatment of patients with idiopathic inflammatory myopathy‏ ‎‡9 1‏
919 ‎‡a screeningofpulmonaryhypertensioninaspanishcohortofpatientswithsystemicsclerosis‏ ‎‡A Screening of pulmonary hypertension in a Spanish cohort of patients with systemic sclerosis‏ ‎‡9 1‏
919 ‎‡a severeimatinibinducedhepatotoxicity‏ ‎‡A [Severe imatinib-induced hepatotoxicity]‏ ‎‡9 1‏
919 ‎‡a severeinfectionsinacohortofpatientswithsystemiclupuserythematosus‏ ‎‡A [Severe infections in a cohort of patients with systemic lupus erythematosus]‏ ‎‡9 1‏
919 ‎‡a softtissuevisualizationwith99mtchdpinacaseofdermatomyositis‏ ‎‡A [Soft tissue visualization with 99m Tc-HDP in a case of dermatomyositis]‏ ‎‡9 1‏
919 ‎‡a autoimmunediseaseassociatedil2ralocusisinvolvedintheclinicalmanifestationsofsystemicsclerosis‏ ‎‡A The autoimmune disease-associated IL2RA locus is involved in the clinical manifestations of systemic sclerosis‏ ‎‡9 1‏
919 ‎‡a tocilizumabfortreatingrefractoryhaemolyticanaemiainapatientwithsystemiclupuserythematosus‏ ‎‡A Tocilizumab for treating refractory haemolytic anaemia in a patient with systemic lupus erythematosus‏ ‎‡9 1‏
919 ‎‡a transversemyelitisinsystemiclupuserythematosus‏ ‎‡A Transverse myelitis in systemic lupus erythematosus‏ ‎‡9 1‏
919 ‎‡a treatmentwithrituximabofautoimmunediseaseresultsfromaadeasregistry‏ ‎‡A [Treatment with rituximab of autoimmune disease: results from AADEA's registry]‏ ‎‡9 1‏
919 ‎‡a tuberculosisinacohortofpatientswithsystemiclupuserythematosus‏ ‎‡A [Tuberculosis in a cohort of patients with systemic lupus erythematosus].‏ ‎‡9 1‏
919 ‎‡a usefulnessofbrainspectwithhmpao99mtcandpsychologicaltestsfordiagnosisofneurologicalinvolvementinbehcetsdisease‏ ‎‡A Usefulness of brain SPECT with HMPAO-99mTc and psychological tests for diagnosis of neurological involvement in Behçet's disease‏ ‎‡9 1‏
919 ‎‡a variantsoftheifi16geneaffectingthelevelsofexpressionofmrnaareassociatedwithsusceptibilitytobehcetdisease‏ ‎‡A Variants of the IFI16 gene affecting the levels of expression of mRNA are associated with susceptibility to Behçet disease.‏ ‎‡9 1‏
919 ‎‡a vasculitisdelsistemanerviosocentraldepresentacionseudotumoralenlaartritisreumatoide‏ ‎‡A Vasculitis del sistema nervioso central de presentación seudotumoral en la artritis reumatoide‏ ‎‡9 1‏
919 ‎‡a venousthrombosisandrelapsesinpatientswithbehcetsdiseasedescriptiveanalysisfromspanishnetworkofbehcetsdiseaseregebcohort‏ ‎‡A Venous thrombosis and relapses in patients with Behçet's disease. Descriptive analysis from Spanish network of Behçet's disease (REGEB cohort)‏ ‎‡9 1‏
919 ‎‡a vogtkoyanagiharadadiseasecharacteristicsofaseriesofandalusianpatients‏ ‎‡A [Vogt-Koyanagi-Harada disease. Characteristics of a series of Andalusian patients]‏ ‎‡9 1‏
919 ‎‡a replicationstudyconfirmstheassociationoftnfsf4‏ ‎‡A A replication study confirms the association of TNFSF4‏ ‎‡9 1‏
919 ‎‡a combinedlargescalemetaanalysisidentifiescog6asanovelsharedrisklocusforrheumatoidarthritisandsystemiclupuserythematosus‏ ‎‡A A combined large-scale meta-analysis identifies COG6 as a novel shared risk locus for rheumatoid arthritis and systemic lupus erythematosus‏ ‎‡9 1‏
946 ‎‡a b‏ ‎‡9 1‏
996 ‎‡2 BNC|981058616023406706‏
996 ‎‡2 BNE|XX1059817‏
996 ‎‡2 BNE|XX890806‏
996 ‎‡2 BNE|XX894412‏
996 ‎‡2 BNCHL|10000000000000000134643‏
996 ‎‡2 RERO|A013659749‏
996 ‎‡2 RERO|A005527078‏
996 ‎‡2 ICCU|SBLV274584‏
996 ‎‡2 DNB|137737076‏
996 ‎‡2 BNC|981058530353706706‏
996 ‎‡2 SUDOC|268249741‏
996 ‎‡2 LC|ns2021002211‏
996 ‎‡2 NSK|000715517‏
996 ‎‡2 ISNI|0000000072351847‏
996 ‎‡2 BNE|XX1309140‏
996 ‎‡2 LC|n 88017567‏
996 ‎‡2 BIBSYS|90715702‏
996 ‎‡2 LC|no2009180766‏
996 ‎‡2 BNE|XX1328203‏
996 ‎‡2 LC|n 87935523‏
996 ‎‡2 ISNI|0000000060633265‏
996 ‎‡2 LC|no 98120675‏
996 ‎‡2 NUKAT|n 2006132222‏
996 ‎‡2 LC|n 88200402‏
996 ‎‡2 SUDOC|165861827‏
996 ‎‡2 BNC|981060913938706706‏
996 ‎‡2 LC|n 85301102‏
996 ‎‡2 BNE|XX1586413‏
996 ‎‡2 BNE|XX889751‏
996 ‎‡2 ISNI|0000000503983513‏
996 ‎‡2 DNB|1045699888‏
996 ‎‡2 PTBNP|949018‏
996 ‎‡2 BNE|XX1289014‏
996 ‎‡2 BNE|XX1304200‏
996 ‎‡2 J9U|987007454659205171‏
996 ‎‡2 ISNI|000000010778423X‏
996 ‎‡2 PTBNP|1710396‏
996 ‎‡2 SUDOC|181056143‏
996 ‎‡2 BNE|XX1023021‏
996 ‎‡2 DNB|105753286X‏
996 ‎‡2 CAOONL|ncf11298532‏
996 ‎‡2 BNE|XX5610055‏
996 ‎‡2 ISNI|0000000434915057‏
996 ‎‡2 LC|n 78068006‏
996 ‎‡2 NTA|398394857‏
996 ‎‡2 LC|no2007078911‏
996 ‎‡2 SUDOC|075773015‏
996 ‎‡2 ISNI|0000000034068717‏
996 ‎‡2 NTA|236534688‏
996 ‎‡2 DNB|114716309X‏
996 ‎‡2 BNE|XX4606293‏
996 ‎‡2 BNCHL|10000000000000000267225‏
996 ‎‡2 SUDOC|150624603‏
996 ‎‡2 RERO|A006244970‏
996 ‎‡2 BNE|XX1576859‏
996 ‎‡2 NTA|20209782X‏
996 ‎‡2 DNB|1023953773‏
996 ‎‡2 LC|ns2021000336‏
996 ‎‡2 DNB|104554169‏
996 ‎‡2 BNC|981058522134806706‏
996 ‎‡2 J9U|987007460521705171‏
996 ‎‡2 BNE|XX4775163‏
996 ‎‡2 ISNI|0000000059834086‏
996 ‎‡2 DNB|1036856593‏
996 ‎‡2 DNB|1023089718‏
996 ‎‡2 SUDOC|078953685‏
996 ‎‡2 LIH|LNB:B_a_4_d_;=B_b_‏
996 ‎‡2 BNC|981061224328506706‏
996 ‎‡2 BNE|XX1763080‏
996 ‎‡2 SUDOC|112624634‏
996 ‎‡2 LC|n 88675585‏
996 ‎‡2 BNF|13488883‏
996 ‎‡2 LC|no2011088157‏
996 ‎‡2 LC|n 82047612‏
996 ‎‡2 NUKAT|n 2018178083‏
996 ‎‡2 RERO|A000079910‏
996 ‎‡2 ISNI|0000000059284299‏
996 ‎‡2 BNF|17803051‏
996 ‎‡2 SUDOC|154078239‏
996 ‎‡2 NTA|239318544‏
996 ‎‡2 BNCHL|10000000000000000081053‏
996 ‎‡2 ISNI|0000000033545374‏
996 ‎‡2 BNF|15120033‏
996 ‎‡2 LC|ns2012002558‏
996 ‎‡2 ISNI|0000000047566002‏
996 ‎‡2 BNE|XX1294494‏
996 ‎‡2 BAV|495_163867‏
996 ‎‡2 BNF|17887293‏
996 ‎‡2 ISNI|0000000077114584‏
996 ‎‡2 RERO|A025974662‏
996 ‎‡2 NTA|070283842‏
996 ‎‡2 BNE|XX5449276‏
996 ‎‡2 PLWABN|9812218107705606‏
996 ‎‡2 SUDOC|220242593‏
996 ‎‡2 BNC|981058527485606706‏
996 ‎‡2 LC|ns2016000493‏
996 ‎‡2 DNB|130029101X‏
996 ‎‡2 BNE|XX4862718‏
996 ‎‡2 LC|ns2013000653‏
996 ‎‡2 LC|n 84072378‏
996 ‎‡2 ISNI|0000000061133895‏
996 ‎‡2 RERO|A008700616‏
996 ‎‡2 BNE|XX1178482‏
996 ‎‡2 BNE|XX1647034‏
996 ‎‡2 SUDOC|085995932‏
996 ‎‡2 BNE|XX1437175‏
996 ‎‡2 LC|n 2019017676‏
996 ‎‡2 SUDOC|237157756‏
996 ‎‡2 LC|no2010201113‏
996 ‎‡2 SUDOC|272836206‏
996 ‎‡2 BNE|XX1307182‏
996 ‎‡2 BIBSYS|1642068490964‏
996 ‎‡2 BNE|XX4689201‏
996 ‎‡2 BNE|XX1269545‏
996 ‎‡2 ISNI|0000000064604867‏
996 ‎‡2 ISNI|0000000052025331‏
996 ‎‡2 J9U|987007273454205171‏
996 ‎‡2 CAOONL|ncf11253989‏
996 ‎‡2 LC|no2010019859‏
996 ‎‡2 BNE|XX844117‏
996 ‎‡2 DNB|1193072387‏
996 ‎‡2 BNE|XX980295‏
996 ‎‡2 BNE|XX870259‏
996 ‎‡2 DNB|138752648‏
996 ‎‡2 CAOONL|ncf13751022‏
996 ‎‡2 BNF|14513870‏
996 ‎‡2 BNCHL|10000000000000000814095‏
996 ‎‡2 LC|no2017121416‏
996 ‎‡2 BNE|XX882884‏
996 ‎‡2 ISNI|0000000048811540‏
996 ‎‡2 SUDOC|070015759‏
996 ‎‡2 BNC|981060544722406706‏
996 ‎‡2 ISNI|000000005452285X‏
996 ‎‡2 ISNI|0000000080084371‏
996 ‎‡2 BNE|XX5042517‏
996 ‎‡2 DNB|1157366929‏
996 ‎‡2 BNC|981058611130206706‏
996 ‎‡2 LC|no2016102775‏
996 ‎‡2 BNE|XX4837242‏
996 ‎‡2 LC|ns2019002921‏
996 ‎‡2 BNE|XX4856459‏
996 ‎‡2 ISNI|0000000049095531‏
996 ‎‡2 BNE|XX4832894‏
996 ‎‡2 DNB|1155950410‏
996 ‎‡2 BNE|XX900064‏
996 ‎‡2 J9U|987007277111505171‏
996 ‎‡2 BNC|981058616314606706‏
996 ‎‡2 LC|ns2013001484‏
996 ‎‡2 LC|no 00007636‏
996 ‎‡2 DNB|1234487020‏
996 ‎‡2 DNB|1169144772‏
996 ‎‡2 LC|no2011010737‏
996 ‎‡2 DNB|1057421758‏
996 ‎‡2 ISNI|000000006062027X‏
996 ‎‡2 J9U|987007356173105171‏
996 ‎‡2 SUDOC|192600974‏
996 ‎‡2 ISNI|0000000049949170‏
996 ‎‡2 BNF|16509679‏
996 ‎‡2 NTA|128963654‏
996 ‎‡2 NII|DA05283999‏
996 ‎‡2 SUDOC|172159504‏
996 ‎‡2 ISNI|0000000059769026‏
996 ‎‡2 SUDOC|029491738‏
996 ‎‡2 DNB|1056373504‏
996 ‎‡2 LC|nr2005018814‏
996 ‎‡2 SUDOC|165101067‏
996 ‎‡2 BNCHL|10000000000000000010443‏
996 ‎‡2 DNB|1056616822‏
996 ‎‡2 SUDOC|035779446‏
996 ‎‡2 SUDOC|033154724‏
996 ‎‡2 BNC|981058516727806706‏
996 ‎‡2 NUKAT|n 2021202174‏
996 ‎‡2 SUDOC|11506222X‏
996 ‎‡2 BLBNB|000301827‏
996 ‎‡2 J9U|987007369466305171‏
996 ‎‡2 LC|no2010190352‏
996 ‎‡2 BNE|XX1547640‏
996 ‎‡2 BIBSYS|90745855‏
996 ‎‡2 SUDOC|030097401‏
996 ‎‡2 ISNI|0000000059514509‏
996 ‎‡2 J9U|987012501802005171‏
996 ‎‡2 BNF|14497914‏
996 ‎‡2 ISNI|0000000416494447‏
996 ‎‡2 NII|DA02012237‏
996 ‎‡2 DNB|133037193‏
996 ‎‡2 BNE|XX5607079‏
996 ‎‡2 ISNI|0000000119719822‏
996 ‎‡2 LC|no2014046210‏
996 ‎‡2 ISNI|0000000078847683‏
996 ‎‡2 LC|n 97091993‏
996 ‎‡2 LC|no2007054547‏
996 ‎‡2 BNE|XX1197603‏
996 ‎‡2 LC|no2011130819‏
996 ‎‡2 BNE|XX5587270‏
996 ‎‡2 J9U|987007599153805171‏
996 ‎‡2 LC|n 96004168‏
996 ‎‡2 BNE|XX1008682‏
996 ‎‡2 BNE|XX1299132‏
996 ‎‡2 DNB|170213242‏
996 ‎‡2 LC|no2014071069‏
996 ‎‡2 LC|n 88612899‏
996 ‎‡2 BNE|XX975545‏
996 ‎‡2 BNE|XX1173080‏
996 ‎‡2 LC|no2011086800‏
996 ‎‡2 SUDOC|193206617‏
996 ‎‡2 DNB|1060923890‏
996 ‎‡2 ISNI|000000050152118X‏
996 ‎‡2 J9U|987007257534705171‏
996 ‎‡2 ISNI|0000000060158150‏
996 ‎‡2 LC|n 82096930‏
996 ‎‡2 ISNI|0000000060967126‏
996 ‎‡2 RERO|A008961003‏
996 ‎‡2 LC|n 78016445‏
996 ‎‡2 ISNI|0000000059488451‏
996 ‎‡2 BNE|XX1304285‏
996 ‎‡2 BNF|14410403‏
996 ‎‡2 ISNI|0000000115789874‏
996 ‎‡2 BNE|XX1090221‏
996 ‎‡2 SUDOC|077434412‏
996 ‎‡2 LC|no2007026105‏
996 ‎‡2 ISNI|0000000047668340‏
996 ‎‡2 RERO|A024534420‏
996 ‎‡2 JPG|500006449‏
996 ‎‡2 BNE|XX1004233‏
996 ‎‡2 DNB|171424158‏
996 ‎‡2 ISNI|0000000059997424‏
996 ‎‡2 LC|n 2022031376‏
996 ‎‡2 LC|no 00067848‏
996 ‎‡2 BNE|XX975494‏
996 ‎‡2 BNE|XX968906‏
996 ‎‡2 NTA|132391848‏
996 ‎‡2 SUDOC|086838806‏
996 ‎‡2 LC|no2007066969‏
996 ‎‡2 ISNI|0000000078235134‏
996 ‎‡2 BNE|XX1181945‏
996 ‎‡2 BNE|XX852459‏
996 ‎‡2 ISNI|0000000037206441‏
996 ‎‡2 LC|ns2012000387‏
996 ‎‡2 BNC|981058526636106706‏
996 ‎‡2 LC|no2004073187‏
996 ‎‡2 BIBSYS|14037981‏
996 ‎‡2 LC|ns2018001518‏
996 ‎‡2 BNE|XX1676302‏
996 ‎‡2 SUDOC|129766097‏
996 ‎‡2 LC|n 2022057617‏
996 ‎‡2 BNE|XX6125821‏
996 ‎‡2 BNF|11277934‏
996 ‎‡2 SUDOC|200877070‏
996 ‎‡2 DNB|1182598889‏
996 ‎‡2 LC|no2009153128‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏